Antifungal Potential of Moringa Olifera Against Otomycosis
Early Phase 1
Completed
- Conditions
- Otomycosis
- Interventions
- Drug: Ear DropDrug: Moringa oleifera leaf 10mg/100ml
- Registration Number
- NCT04768829
- Lead Sponsor
- Deraya University
- Brief Summary
patients with Otomycosis were recognized by an ENT specialist. 20 patients were distributed randomly into two groups. The first group will be treated with Nystatin ear drops twice daily. The second group will be treated with Moringa ear drops. patients will be examined endoscopically by the ENT specialist. patient's swabs will be isolated and analyzed by ELISA.
- Detailed Description
Inclusion criteria:
(1) Otomycosis .
Exclusion criteria:
1. tympanic membrane perforation;
2. concurrent immune suppression,
3. and concurrent bacterial infection.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
- Otomycosis
- ear inflammation
Exclusion Criteria
- tympanic membrane perforation
- concurrent immune suppression,
- concurrent bacterial infection.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo group Ear Drop Nystatin ear drops formulations prepared as intervention except for the addition of Moringa prepared using biodegradable polymers in aseptic condition and tested for sensitivity Moringa group Moringa oleifera leaf 10mg/100ml Moringa ear drops prepared using biodegradable polymers in aseptic condition and tested for sensitivity
- Primary Outcome Measures
Name Time Method Identification of different microorganisms infected ear up to 1 month Patients swabs (microorganisms concentration)
Number of participants recovered with clear endoscopic examination one week Number of participants recovered with clear endoscopic examination
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Soad A. Mohamad
🇪🇬Minya, المنيا, Egypt